Shares of Symbotic sank as much as 10.3% this week after the warehouse-robotics company delivered a quarter that looked great on paper but left investors questioning what comes next. The AI-powered automation firm posted a 22% year-over-year revenue increase to $721 million and swung to a $55 million GAAP profit from a $21 million loss a year earlier — yet the stock cratered, landing near $42.52, well below its 52-week high of $87.88.
The Numbers Were Strong, But One Metric Spoiled the Party
Symbotic reported $0.09 in adjusted earnings per share, missing analysts' consensus estimate of $0.13 by four cents, even as revenue of $720.84 million topped the $715 million expectation.
That 25% earnings shortfall overshadowed the revenue beat and renewed concerns about the company's ability to convert rapid growth into consistent profits. For shareholders, a revenue beat paired with an earnings miss signals that costs are rising faster than Wall Street had modeled.
Margins Hit a Ceiling Just When They Needed to Climb
Higher-margin software and services revenue contributed to a non-GAAP gross margin of 25% in the quarter , but management guided that Q4 gross margin should be "in line with or slightly below" that 25% level, and system starts would match or dip below the 11 recorded in Q3. That flat guidance is the crux of the selloff: investors who bought at higher prices were betting on accelerating profitability, not a plateau.
A Massive Backlog Isn't Converting Fast Enough
Symbotic carries a $22.7 billion backlog — roughly 10 times its 2025 revenue — yet expenses rose as systems in deployment grew to 70 from 46 a year earlier.
Management now signals broader rollouts of newer, smaller systems likely in 2028 rather than the earlier 2026-to-2027 timeline, feeding concern that new products need longer test cycles before they scale.
What Keeps the Bull Case Alive
The company expects positive free cash flow in Q4 and on an annual basis, and still holds $1.7 billion in cash — a war chest that allows it to keep investing without fresh financing.
Needham reaffirmed a Buy rating with a $75 price target , and a new healthcare customer, Medline — the nation's largest medical-surgical supplier — signals diversification beyond grocery.
The bottom line: Symbotic is profitable, growing, and cash-rich. But until margins visibly accelerate and new product timelines tighten, Wall Street is pricing the stock for what it can prove today — not the $22.5 billion in promises on the backlog.